

# Microsampling in a clinical context – VAMS as a case example


**Christophe STOVE**

Laboratory of Toxicology,  
Faculty of Pharm. Sciences,  
Ghent University, Belgium










[christophe.stove@ugent.be](mailto:christophe.stove@ugent.be)

# PRESENTATION OVERVIEW

- General
- Hct independence of VAMS
- VAMS for anti-epileptic TDM
- VAMS for Co monitoring
- VAMS for HbA1c monitoring




# INTRO: Challenges of Volumetric Absorptive Microsampling

-  Limited amount of sample & analyte available
  -  Sample quality (+ contamination risk)
  -  Recovery issues (hematocrit!)
  -  Stability issues
  -  ~~Volume Issues (related to paper saturation)~~
  -  ~~Spot inhomogeneity ('chromatography effect')~~
  -  ~~Hematocrit effect (spreading)~~
  -  Possible differences between capillary & venous blood
  -  Interpretation (blood [ ] vs. plasma [ ])
- More extensive validation required

## Volumetric Absorptive Microsampling: A Dried Sample Collection Technique for Quantitative Bioanalysis

Philip Denniff and Neil Spooner\*



Bioanalytical Science and Toxicokinetics, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Research and Development, Ware, Hertfordshire SG12 0DP, United Kingdom



**Artificial samples:  
≠ Hct by adding or  
removing plasma**

**What about real  
(clinical) samples?**



# Volumetric Absorptive Microsampling: Hct independence






## Study Set-up:

- Use left-over EDTA-anticoagulated blood from patients ( $\neq$  hospital departments)
- Compare liquid blood – VAMS – DBS
- Analytes: caffeine & paraxanthine



# Volumetric Absorptive Microsampling: Hct independence



# Volumetric Absorptive Microsampling: Hct independence





# Volumetric Absorptive Microsampling: Hct independence






# Volumetric Absorptive Microsampling: Hct independence



# Volumetric Absorptive Microsampling: Hct independence



## Evaluation of impact of hematocrit on recovery:


- VAMS: Similar extraction procedure as for DBS
- ↓ recovery at higher hematocrits

Absolute recovery and matrix effect data (n = 3) for caffeine and paraxanthine at two concentration levels in VAMS samples prepared using whole blood with varying Hct values.

	Hct	Caffeine		Paraxanthine	
		Low QC	High QC	Low QC	High QC
Absolute recovery (mean ± SD, %)	0.21	101.45 ± 2.26	101.79 ± 0.67	86.98 ± 1.52	87.14 ± 1.75
	0.42	101.30 ± 1.28	100.53 ± 2.67	84.70 ± 3.53	84.33 ± 1.38
	0.48	93.86 ± 0.89	91.08 ± 2.03	75.48 ± 0.60	75.93 ± 1.09
	0.62	92.01 ± 4.80	92.91 ± 4.74	73.51 ± 1.60	77.72 ± 5.69

**The calibration line had been set up at a relative high Ht;  
⇒ because of the impact of the Ht, recovery of the vast majority  
of the samples will be slightly higher than that of the calib.'s**

# Volumetric Absorptive Microsampling: Hct independence




## Evaluation of impact of hematocrit on recovery:

- VAMS: Similar extraction procedure as for DBS
- ↓ recovery at higher hematocrits
- No impact on matrix effect

Absolute recovery and matrix effect data (n = 3) for caffeine and paraxanthine at two concentration levels in VAMS samples prepared using whole blood with varying Hct values.

	Hct	Caffeine		Paraxanthine	
		Low QC	High QC	Low QC	High QC
Absolute recovery (mean ± SD, %)	0.21	101.45 ± 2.26	101.79 ± 0.67	86.98 ± 1.52	87.14 ± 1.75
	0.42	101.30 ± 1.28	100.53 ± 2.67	84.70 ± 3.53	84.33 ± 1.38
	0.48	93.86 ± 0.89	91.08 ± 2.03	75.48 ± 0.60	75.93 ± 1.09
	0.62	92.01 ± 4.80	92.91 ± 4.74	73.51 ± 1.60	77.72 ± 5.69
Absolute matrix effect (mean ± SD, %)	0.21	104.29 ± 3.37	100.49 ± 1.54	101.46 ± 2.49	99.69 ± 2.01
	0.42	101.16 ± 0.53	99.52 ± 1.71	98.28 ± 3.28	99.48 ± 0.34
	0.48	97.46 ± 0.50	97.48 ± 0.99	99.03 ± 2.73	99.10 ± 1.31
	0.62	103.07 ± 2.09	98.36 ± 0.31	100.58 ± 4.26	99.48 ± 1.78

# Volumetric Absorptive Microsampling: Hct independence




Might there be a blood-VAMS difference between real samples & spiked samples?:

→ Determine concentrations in a spiked sample and a real sample (following caffeine consumption) (n=3)

		VAMS ( $\mu\text{g mL}^{-1}$ ) mean $\pm$ SD [% CV]	Whole blood ( $\mu\text{g mL}^{-1}$ ) mean $\pm$ SD; [CV]	Difference VAMS- whole blood (%)
Caffeine	Spiked samples	1.03 $\pm$ 0.01 [1.36]	1.01 $\pm$ 0.01 [1.31]	1.49
	Incurred samples	1.12 $\pm$ 0.01 [1.07]	1.04 $\pm$ 0.02 [1.74]	6.86*
Paraxanthine	Spiked samples	0.81 $\pm$ 0.01 [1.45]	0.81 $\pm$ 0.01 [0.62]	0.35
	Incurred samples	0.82 $\pm$ 0.02 [1.95]	0.77 $\pm$ 0.01 [0.88]	6.35*

\* significant difference ( $p < 0.05$ )

⇒ **Incurred (real) samples show a slight overestimation with VAMS, as compared to liquid blood**




## Conclusions of our evaluation of VAMS:

- Sampling is straightforward (even more than with DBS)
- VAMS overcomes the hematocrit bias that is seen in DBS analysis
- For the analytes investigated (caffeine & paraxanthine), a slight positive bias (i.e. overestimation) was observed

This positive bias may be accounted for by 2 factors:

- VAMS are more subject to a hematocrit effect on recovery than DBS (our calibr. line being set up at a higher Ht than that of most samples)
- VAMS resulted in a slight overestimation of incurred but not spiked samples, when compared with blood




## Conclusions of our evaluation of VAMS:

- Sampling is straightforward (even more than with DBS)
- VAMS overcomes the hematocrit bias that is seen in DBS analysis
- For the analytes investigated (caffeine & paraxanthine), a slight positive bias (i.e. overestimation) was observed

This positive bias may be accounted for by 2 factors:

- VAMS are more subject to a hematocrit effect on recovery than DBS (our calibr. line being set up at a higher Ht than that of most samples)
- VAMS resulted in a slight overestimation of incurred but not spiked samples, when compared with blood




## Conclusions of our evaluation of VAMS:

- Sampling is straightforward (even more than with DBS)
- VAMS overcomes the hematocrit bias that is seen in DBS analysis
- For the analytes investigated (caffeine & paraxanthine), a slight positive bias (i.e. overestimation) was observed

This positive bias may be accounted for by 2 factors:


- VAMS are more subject to a hematocrit effect on recovery than DBS (our calibr. line being set up at a higher Ht than that of most samples)
- VAMS resulted in a slight overestimation of incurred but not spiked samples, when compared with blood

# Volumetric Absorptive Microsampling: (potential) analytes






# Volumetric Absorptive Microsampling: (potential) analytes



# Volumetric Absorptive Microsampling: (potential) analytes



# Volumetric Absorptive Microsampling: small molecules



Therapeutic  
Drugs

- Antihypertensives
- Antiretrovirals
- Antimalarials
- Antibiotics
- Antidiabetics
- Analgesics
- Immunosuppressants
- Anticonvulsants
- Antipsychotics
- ...



Drugs of Abuse

- Phosphatidylethanol
- Cotinine
- Benzodiazepines
- Heroin, Morphine, 6-Monoacetylmorphine
- Methadone, Buprenorphine
- Fentanyl
- Cocaine, benzoylecgonine, cocaethylene
- MDMA (ecstasy), MDA
- Cannabinoids
- Gamma-hydroxybutyric acid (GHB)
- ...

**TDM**

**CLIN  
TOX**

# Volumetric Absorptive Microsampling: small molecules



Therapeutic  
Drugs

- Antihypertensives
- Antiretrovirals
- Antimalarials
- **Antibiotics**
- Antidiabetics
- **Analgesics**
- **Immunosuppressants**
- **Anticonvulsants**
- **Antipsychotics**
- ...



Drugs of Abuse


- **Phosphatidylethanol**
- Cotinine
- Benzodiazepines
- **Heroin**, Morphine, 6-Monoacetylmorphine
- Methadone, Buprenorphine
- Fentanyl
- **Cocaine**, benzoylecgonine, cocaethylene
- MDMA (ecstasy), MDA
- **Cannabinoids**
- Gamma-hydroxybutyric acid (GHB)
- ...

TDM

CLIN  
TOX

# VAMS for TDM of conventional anti-epileptics

## Anti-epileptic drugs

Classical or First-generation AEDs	New-generation AEDs
Valproic acid, phenobarbital, phenytoin, carbamazepine, primidone and ethosuximide	Gabapentin, lamotrigine, oxcarbazepine, topiramate, vigabatrine, ... .
<p>→ Narrow therapeutic ranges → inter-individual variability in PK (ADME)</p> <p style="text-align: center;"></p> <p>Therapy optimization and individualization quite challenging</p>	<p>→ Wider therapeutic ranges → Fewer serious adverse effects</p>


## TDM of AEDs:

- **Excellent tool for therapy optimization & individualization**
- **Helpful in maximizing safety and benefits**


# VAMS for TDM of conventional anti-epileptics

## Study objective


Determination and quantification of 5 AEDs and 1 active metabolite




CBZ




PB




PHT



VPA




CBZ-E




OXC

# VAMS for TDM of conventional anti-epileptics


## Sample preparation



Preparing the VAMS



Drying for 2 hours



Removing of VAMS tip



Extraction  
with 100  $\mu$ L  
80/20  
ACN/H<sub>2</sub>O + IS  
+ 5mM  
amm.acet



Thermomixer:  
10min; 60°C; 1000 rpm



Centrifugation:  
10min; 10 000 g



70  $\mu$ L supernatant +  
70  $\mu$ L H<sub>2</sub>O + 5mM  
amm.acet



LC-  
MS/MS

# VAMS for TDM of conventional anti-epileptics

## LC-MS/MS

### Chromatography (Waters Acquity UPLC®)

- Column: Chromolith® reversed phase (RP)-18 endcapped (100x4.60 mm; 5 µm)
- Mobile phase: 5mM ammonium acetate in H<sub>2</sub>O (A) and in ACN/H<sub>2</sub>O 95/5 (B)
- Flow: 1.4 mL/min
- Column temperature: 45°C
- Gradient elution
- Total runtime: 10 min (including negative, positive run, washing and equilibrating)

### Mass spectrometry (Sciex API 4000™)

- TurbolonSpray® probe (ESI)
- MRM™ mode
- Positive ion mode: CBZ, CBZ-E, OXC
- Negative ion mode: VPA, PB, PHT




Use of deuterium-labeled internal standards: CBZ-d10, CBZ-E-d10, OXC-d4, VPA-d6, PB-d5, PHT-d10



# VAMS for TDM of conventional anti-epileptics

## Chromatogram


Negative ion mode (LLOQ)



# VAMS for TDM of conventional anti-epileptics




## Chromatogram

Positive ion mode (LLOQ)






# VAMS for TDM of conventional anti-epileptics

## Validation: calibration model



# VAMS for TDM of conventional anti-epileptics

## Validation: calibration model



# VAMS for TDM of conventional anti-epileptics

## Validation: accuracy and precision

VPA	Accuracy %	Within run precision %	Between run precision %
LLOQ	-15	7.5	7.5
Low QC	18	3.8	8.2
Mid QC	-1	5.6	5.6
High QC	-1	8.3	8.3

PHT	Accuracy %	Within run precision %	Between run precision %
LLOQ	4	8.6	8.6
Low QC	1	6.6	6.6
Mid QC	4	7.9	7.9
High QC	5	4.1	7.7

PB	Accuracy %	Within run precision %	Between run precision %
LLOQ	-1	9.8	9.8
Low QC	-1	7.3	7.8
Mid QC	-3	4.5	4.5
High QC	2	3.9	6.2

# VAMS for TDM of conventional anti-epileptics

## Validation: accuracy and precision

CBZ	Accuracy %	Within run precision %	Between run precision %
LLOQ	10	8.8	8.8
Low QC	1	7.5	7.5
Mid QC	8	6.0	6.0
High QC	2	9.0	9.0

CBZ-E	Accuracy %	Within run precision %	Between run precision
LLOQ	4	7.7	7.7
Low QC	14	6.5	6.6
Mid QC	8	5.3	5.3
High QC	5	5.1	5.1

OXC	Accuracy %	Within run precision %	Between run precision %
LLOQ	-40	6.4	6.4
Low QC	5	5.2	6.3
Mid QC	1	4.1	5.6
High QC	11	6.4	6.4

# VAMS for TDM of conventional anti-epileptics

## Validation: matrix effects

Hct range: 0.335 – 0.495

VPA			PHT			PB		
IS corrected matrix effect	Low QC %	High QC %	IS corrected matrix effect	Low QC %	High QC %	IS corrected matrix effect	Low QC %	High QC %
Matrix 1	103	101	Matrix 1	96	98	Matrix 1	98	98
Matrix 2	103	102	Matrix 2	94	96	Matrix 2	96	95
Matrix 3	104	102	Matrix 3	97	91	Matrix 3	99	96
Matrix 4	100	99	Matrix 4	104	93	Matrix 4	101	94
Matrix 5	103	104	Matrix 5	97	99	Matrix 5	98	97
Matrix 6	103	99	Matrix 6	102	95	Matrix 6	97	95
Average	103	101	Average	99	95	Average	98	96
CV%	1.21	1.83	CV%	3.91	3.01	CV%	1.92	1.58

# VAMS for TDM of conventional anti-epileptics

## Validation: matrix effects

Hct range: 0.335 – 0.495

CBZ			CBZ-E			OXC		
IS corrected matrix effect	Low QC %	High QC %	IS corrected matrix effect	Low QC %	High QC %	IS corrected matrix effect	Low QC %	High QC %
Matrix 1	91	91	Matrix 1	96	97	Matrix 1	116	83
Matrix 2	96	89	Matrix 2	93	100	Matrix 2	117	86
Matrix 3	92	91	Matrix 3	98	96	Matrix 3	116	88
Matrix 4	94	91	Matrix 4	96	96	Matrix 4	120	89
Matrix 5	93	90	Matrix 5	95	99	Matrix 5	119	89
Matrix 6	92	90	Matrix 6	96	106	Matrix 6	120	91
Average	93	90	Average	95	99	Average	118	88
CV%	1.67	0.93	CV%	1.70	3.97	CV%	1.46	3.15







=> Fulfills acceptance criteria, except for Low QC of OXC



# VAMS for TDM of conventional anti-epileptics

## Validation: haematocrit effect

Low Hct: 0.21  
Mid Hct: 0.42  
High Hct: 0.62




# VAMS for TDM of conventional anti-epileptics


## Conclusion and future perspectives

- A method for the quantification of conventional anti-epileptics was successfully set up
- The calibration lines cover relevant concentration ranges
- Accuracy and precision overall fulfilled acceptance criteria
- Matrix effects (evaluated at different hematocrits) overall fulfilled acceptance criteria
- At elevated Hct levels there was a slight Hct effect (in terms of somewhat ↓ recovery)
- The method has already been applied successfully on reference samples
- This method will be applied on patients

K-based Hct may be used to calculate serum[ ]




# Volumetric Absorptive Microsampling: (potential) analytes



## Introduction

- MoM prosthesis  
= metal ball + metal cup
- Total hip replacement
- Hip resurfacing
- High prevalence



## Introduction

- Wear and corrosion → debris (Co & Cr)

=> Adverse local tissue reaction

= soft tissue damage, implant loosening,  
implant failure, need for revision

=> Systemic toxicity (Co):

= thyroid dysfunction, cardiomyopathy, neurological changes

= arthroprosthetic cobaltism

## Introduction

- Co-level ~ implant wear  
=> Determination of Co in whole blood or plasma (400  $\mu$ L)
- Cut offs used:
  - 4  $\mu$ g/L: Upper limit acceptable for unilateral HP
  - 5  $\mu$ g/L: Upper limit acceptable for bilateral HP
  - 10  $\mu$ g/L: More pronounced wear
  - 20  $\mu$ g/L: Substantial wear & systemic toxicity possible  
Revision should be considered

## Introduction

- Goals:
  - Home-based patient sampling
  - Easier sample transfer to the lab/between labs
- Collaboration:
  - Ghent University Hospital → routine Co analysis
  - Department of Analytical Chemistry → ICP-MS
  - Laboratory of Toxicology → microsampling

# Trace elements in VAMS: Co

Analytica Chimica Acta 941 (2016) 1–9



ELSEVIER

Contents lists available at ScienceDirect

Analytica Chimica Acta

journal homepage: [www.elsevier.com/locate/aca](http://www.elsevier.com/locate/aca)




Determination of ultra-trace amounts of prosthesis-related metals in whole blood using volumetric absorptive micro-sampling and tandem ICP – Mass spectrometry



Eduardo Bolea-Fernandez <sup>a</sup>, Kim Phan <sup>a</sup>, Lieve Balcaen <sup>a</sup>, Martín Resano <sup>b</sup>, Frank Vanhaecke <sup>a,\*</sup>

<sup>a</sup> Ghent University, Department of Analytical Chemistry, Campus Sterre, Krijgslaan 281-S12, 9000 Ghent, Belgium

<sup>b</sup> University of Zaragoza, Aragón Institute of Engineering Research (I3A), Department of Analytical Chemistry, Pedro Cerbuna 12, 50009 Zaragoza, Spain





## Materials and methods

- ICP-MS: Agilent 7900
- Co 59 & Rh 103
- 10 measurements of 1 sec per element → average



## Materials and methods



- VAMS vs. DBS
  - Background lower in VAMS
- VAMS
  - No Hct effect
    - = fixed sample volume
  - Cave: Hct effect on extraction

# Trace elements in VAMS: Co

## Materials and methods

- Sample prep: acidic extraction
  - 1% HCl: still coloured
  - 5% HCl: clear

However: not age independent



## Materials and methods

- Final method:
  - 1) Remove VAMS tip with pipet tip
  - 2) Add 300  $\mu\text{L}$  of  $\text{H}_2\text{O}$  (containing 0.75 ppb Rh)
  - 3) 15 min in thermomixer @ 60°C & 1000 rpm
  - 4) Transfer 250  $\mu\text{L}$  of extract
  - 5) Add 40  $\mu\text{L}$  of subboiled HCl + vortex 1 sec
  - 6) Centrifuge 3 min @ 3000g
  - 7) Transfer 270  $\mu\text{L}$  of supernatant
  - 8) Add 1400  $\mu\text{L}$  of  $\text{H}_2\text{O}$

## Validation

- Calibration model
- LLOQ – ULOQ
- Accuracy & precision
- Carry-over
- Stability
- Recovery
- Hct effect

# Trace elements in VAMS: Co

## Validation

- Calibration model

Based on sum %RE: weighted linear regression  $1/X^2$

Conc. ( $\mu\text{g/L}$ )	Curve 1	Curve 2	Curve 3	Curve 4	Curve 5	Curve 6
3	13.85%	-16.90%	3.02%	-21.27%	-6.74%	0.03%
4	-12.84%	17.90%	-10.77%	-0.28%	7.05%	-3.09%
10	10.92%	-4.91%	31.08%	-0.11%	4.61%	10.66%
20	1.88%	9.32%	-0.84%	1.52%	-3.42%	-9.88%
30	-4.71%	-0.09%	4.12%	5.88%	-1.60%	6.79%
40	2.94%	-7.65%	-10.58%	-7.54%	-0.73%	-3.94%

=> Acceptable based on backcalculated values

=> LLOQ: 3  $\mu\text{g/L}$  & ULOQ: 40  $\mu\text{g/L}$

## Validation

- Accuracy and precision:

QC	Conc ( $\mu\text{g/L}$ )	Accuracy	Intraday precision	Interday precision
LLOQ	3	-5.82%	11.06%	18.80%
LOW	4	-5.48%	14.36%	14.36%
MID	20	1.50%	10.33%	11.21%
HIGH	30	0.37%	4.93%	4.93%
DIL	300	7.04%	14.61%	16.88%


=> Accuracy and precision within 15% (20% for LLOQ)

=> Exception: dilution QC

However, still acceptable from a clinical point of view (extremely elevated)

## Validation


- Stability: RT at least 1 week





## Validation


- Recovery: high & Hct independent



## Conclusion

- Sample prep optimized
- Method validated
  - Sufficiently sensitive
  - No Hct effect, also not on extraction efficiency
  - Stability OK
- Method still has to be applied to patient VAMS
  - Comparison with data from venous blood
  - Comparison venous-capillary blood
- Real home-based sampling to be performed

# Volumetric Absorptive Microsampling: (potential) analytes



# Proteins in VAMS: HbA1c

## HbA1c monitoring in diabetics via sampling @ home via volumetric absorptive microsampling

- HbA1c reflects average glycaemia of last 100-120 days and is predictive for development of vascular complications
- Study with comparison of home sampling (VAMS & DBS) & regular sampling in adults & children




	All	Adults	Children
n	84	40	44
Age (years) median (IQR) <sup>a</sup>	16.5 (12.0-51.8)	54.0 (43.0-64.0)	12.0 (10.0-16.0)
Gender (males/females)	57 M/ 27 F	28 M/ 12 F	29 M/ 15 F
Hospital sampled HbA1c <sup>b</sup> (mmol/mol) median (IQR)	56.3 (49.2-65.7)	58.7 (48.8-66.8)	55.6 (49.7-63.3)

<sup>a</sup> IQR=interquartile range

<sup>b</sup> Hospital sampled: for adults a venous K<sub>2</sub>-EDTA-blood sample and for the children a capillary blood sample in a heparinized capillary tube


# Proteins in VAMS: HbA1c

- Sampling protocol:



# Proteins in VAMS: HbA1c

- Information folder



**Step 1**  
Uncover the VAMS devices by pulling apart the clamshell and fold over the cover to create a handle for easy sample collection + keep within reach




**Step 2**  
Wash hands with warm water for 1 minute and keep the arm down for another minute.




**Step 3**  
Dry fingertip with a clean tissue.




**Step 12**  
Wipe the fingertip clean.



**Step 13**  
Allow the blood on the filter paper to dry for 2 hours at room temperature, and then put in the envelope.




**Step 14**  
Add the closed clamshell with the 2 VAMS devices to the envelope (picture shows only one VAMS device).




**Step 4**  
Take the lancet.



**Step 5**  
Push it to the side of the fingertip. The finger will be automatically pierced.



**Step 6**  
Wipe off the first drop of blood with a clean tissue.



**Step 7**  
Apply the next drop to the premarked circle on the filter paper (fingertip may not touch the paper).




**Step 8**  
Apply the sampler tip of the VAMS device to the surface of the third blood drop (make no contact with the skin).



**Step 9**  
Once you see the sampler tip go fully red, count an additional 2 seconds and then remove the sampler tip from the blood.



**Step 10**  
Apply the sampler tip of the second VAMS device to the surface of the fourth drop of blood (picture shows only one VAMS device).



**Step 11**  
Fold the clamshell back together and press closed.




**Step 15**  
Send the envelope (containing the dried filter paper, the clamshell, the absorbent packet and the filled in questionnaire) to the lab.

# Proteins in VAMS: HbA1c

- Prerequisite: technology readily available at the clinical lab should be used for analysis


Tosoh HLC-723 G8 automated ion-exchange HPLC






# Proteins in VAMS: HbA1c

## Passing-Bablok plots relative to the capillary/venous hospital blood samples

### VAMS (dried & sent)



### DBS (dried & sent)






# Proteins in VAMS: HbA1c

## Passing-Bablok plots relative to the capillary/venous hospital blood samples

### VAMS (dried & sent)




### VAMS (wet)






# Proteins in VAMS: HbA1c

## Passing-Bablok plots relative to the capillary/venous hospital blood samples

### VAMS (dried & sent)



### VAMS (wet)




# Proteins in VAMS: HbA1c

## Bland-Altman plots relative to the capillary/venous hospital blood samples


### VAMS (dried & sent)

**FAILED**



### VAMS (wet)

**ACCEPTED**




Solid line: average difference, with its 95% CI indicated as dotted lines

Dashed lines: lower and upper limit of agreement ( $\pm 1.96$  SD)

Grey area: allowable error according to RCPA Quality Requirements ( $\pm 4$  mmol/mol)

Note the difference in scale!

# Proteins in VAMS: HbA1c





Box and whisker plots indicating the distribution and influence of time between sampling and analysis on HbA1c results in VAMS

# Proteins in VAMS: HbA1c

## Deviating results in dried VAMS are not owing to sampling or measurement variation *in se*

Passing & Bablok regression curve and Bland-Altman plot of **duplicate HbA1c measurements in dried VAMS**



Solid line: average difference, with its 95% CI indicated as dotted lines

Dashed lines: lower and upper limit of agreement ( $\pm 1.96$  SD)

# Proteins in VAMS: HbA1c

## Result of questionnaire


	Demonstration leaflet for sample collection				
	Very clear	Fairly clear	No opinion	Rather confusing	Confusing
Adults	72%	24%	2%	2%	/
Children	72%	19%	2%	7%	/
All	72%	21%	2%	5%	/
	DBS sampling				
	Very convenient	Fairly convenient	No opinion	Rather cumbersome	Cumbersome
Adults	53%	39%	3%	5%	/
Children	46%	44%	/	10%	/
All	50%	42%	1%	7%	/
	VAMS sampling				
	Very convenient	Fairly convenient	No opinion	Rather cumbersome	Cumbersome
Adults	56%	36%	/	8%	/
Children	79%	17%	/	4%	/
All	69%	25%	/	6%	/
	Preferred sampling technique				
	Traditional blood sampling	DBS	VAMS	DBS and VAMS	No opinion
Adults	21%	15%	44%	10%	10%
Children	12%	14%	64%	10%	/
All	16%	14%	56%	10%	4%

## Conclusions

- The majority of patients considered microsampling (either DBS sampling or VAMS) fairly convenient to very convenient
- VAMS was the preferred sampling technique in the majority of patients
- Immediate (<1h) processing of VAMS yielded HbA1c results meeting the strict clinical criteria
  - **Potential to replace capillary microsampling by VAMS in a hospital context**
- Drying of blood is associated with changes in the Hb profile that the HbA1c analyzer cannot cope with
  - **Results obtained from dried VAMS do not meet the clinical acceptance criteria**
- Does this mean that HbA1c cannot be measured in dried microsamples?
  - NO** → **(Use another technique)**
  - **Use a stabilizing approach**

# Proteins in VAMS: HbA1c

Bland-Altman plot of HbA1c measurements in dried blood, stored for 6 days, versus venous hospital blood samples





# VAMS: GENERAL CONCLUSIONS

- **VAMS has been used with success in a wide variety of (clinical) applications**
- **The number of VAMS applications is rapidly increasing**
- **VAMS has been confirmed to be Hct-independent in terms of sampling**
- **Hct is still an important parameter when considering optimization of extraction**
- **VAMS is relatively easy to use and preferred over DBS by patients**
- **VAMS is (likely to be) used (more) for routine clinical applications**

# Acknowledgments

Thanks to my team  
& to **Y**  **U**  
For your attention



# GHEENT

Addictive days and Toxic nights

**TIAFT** 26-30<sup>th</sup> August 2018



BUSY BUILDING THE

**TIAFT2018**

MEETING...